Effect of renal impairment on the pharmacokinetics of exenatide - Wikidata - wikimedia - TriplyDB

Effect of renal impairment on the pharmacokinetics of exenatide

Effect of renal impairment on the pharmacokinetics of exenatide

http://www.wikidata.org/entity/Q36024667

about

The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies Update on the treatment of type 2 diabetes mellitus Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment In vitro metabolic stability of exendin-4: pharmacokinetics and identification of cleavage products Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease.Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide.Exenatide Use in the Management of Type 2 Diabetes Mellitus.Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes.Management of diabetes mellitus in patients with chronic kidney disease Exendin-4 attenuates blast traumatic brain injury induced cognitive impairments, losses of synaptophysin and in vitro TBI-induced hippocampal cellular degeneration Diabetes treatment in patients with renal disease: Is the landscape clear enough?Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide Emerging treatment options for type 2 diabetes Oral glucose-stimulated serum C-peptide predicts successful switching from insulin therapy to liraglutide monotherapy in Japanese patients with type 2 diabetes and renal impairment Emerging role of GLP-1 receptor agonists in the treatment of obesity.Differentiating incretin therapies based on structure, activity, and metabolism: focus on liraglutide.Pharmacokinetic and pharmacodynamic modeling of exendin-4 in type 2 diabetic Goto-Kakizaki rats.Effect of hemodialysis on plasma glucose profile and plasma level of liraglutide in patients with type 2 diabetes mellitus and end-stage renal disease: a pilot study Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective.The efficacy of incretin therapy in patients with type 2 diabetes undergoing hemodialysis.Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects.Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study.Evolution of exenatide as a diabetes therapeutic.Effects of glucagon-like peptide-1 receptor agonists on renal function A review of exenatide as adjunctive therapy in patients with type 2 diabetes.Population pharmacokinetics of exenatide Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials.Glucagon-like peptide-1 analog and insulin combination therapy in the management of adults with type 2 diabetes mellitus.Incretin-based therapies--review of the physiology, pharmacology and emerging clinical experience.The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review.Emerging GLP-1 receptor agonists.Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide.Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment.GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations.Management of post-transplant diabetes.Achieving glycemic control in patients with type 2 diabetes and renal impairment.Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1.Noninsulin glucose-lowering agents for the treatment of patients on dialysis.Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease.

P2860

Q26744317-91B73D4C-BFB7-40E7-8993-419DF34DB716 Q28073342-8337A412-19E0-457C-B558-40012E39087A Q28075368-C7A058AD-6E27-4496-887F-B4D5102F18F9 Q28543699-BCA9DEE8-4D05-4EA0-B2A4-0B0DB8E9D728 Q30249371-DE1F6C5F-4644-4E07-9679-541C9514D55E Q31025919-2DECF8AC-D888-4A5E-8FFB-ABBF1711996E Q33608023-0CD9A5CA-9FCE-4886-B7A7-C642ABE31746 Q33664114-E5D26997-AF58-44B6-9C9F-7AAB0C0ECE9F Q33785308-1A79EF92-E1FC-41B9-BD25-2AB95B1C8D9F Q33792375-5D3322DC-C513-4313-A40A-306142A68695 Q33807853-6F59B3B4-1DDB-4319-85BC-BEBA6F00B7EF Q34068430-B967BEFC-98C9-420A-98A4-FA661E153352 Q34133324-857E384A-AB19-4131-BB4E-4CC7F83F059B Q34381281-15E30EEB-4269-443A-AD9B-783449EA0090 Q34407868-1CEACF1D-6D46-4933-B7FB-A378CE8845DB Q34620465-00D52E83-FCCA-4781-A30C-BB43FE276DDF Q34659509-759C844E-3220-487F-AD94-78D8EEAF7477 Q34702329-BDD27409-436C-438B-91B1-E2BD166CF88B Q34744189-37919592-16A8-4084-A2EE-FF3C598620F1 Q36355550-12708C6F-0971-48B3-8292-E8597B527780 Q36686365-B003A2EA-DCCE-4169-8F0C-F116B4ABB424 Q36729921-6A8ADC64-3F1A-4DF8-94A5-3F719CD07D06 Q36809901-30D16D10-D650-406E-B7A8-ECF3ED2C43F1 Q36877205-02755941-49F4-4610-94D5-9DD7D7E6E196 Q37232679-F2A89A9C-71F7-4513-A4E2-A17F7D5B1B7A Q37403218-E4E22512-D92F-4A41-BFC2-2B601F34B5CF Q37639905-B02E4942-E2C8-4412-BC04-4A9A7D6B7B2E Q37696496-3E31FA92-4AA9-422D-A63A-F1EBE01A02AC Q37763417-3BFA3AEC-6043-4F71-B8D4-AF73502B8977 Q37837059-E29EB172-5607-417F-93BC-7513D493D541 Q37864256-28C1E554-B474-4250-9419-89242EAABB8A Q37929744-F83F3922-6FCA-42BB-9FF3-089971190139 Q37992259-DCB6984D-2B48-4054-ADA4-D80FD6C70779 Q38012068-5601BF4C-0BD7-4D99-8B5C-B3AE806DABF3 Q38055195-BAFB986B-0660-4689-8896-16947418BF31 Q38063169-5C7DDA66-0C88-44C1-A567-1F1F0D3DF130 Q38065109-5305EDEE-CC47-49D6-8A89-405B3CBF04E3 Q38066566-25478679-324C-45F5-8B51-BBBFBAF34717 Q38077451-1D9CC0EF-0362-429C-9B15-2BA0FCDB30E0 Q38086611-B1E77921-1CCD-438B-9612-F51B0322CBCC

P2860

Effect of renal impairment on the pharmacokinetics of exenatide

http://www.wikidata.org/entity/Q36024667

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

Effect of renal impairment on the pharmacokinetics of exenatide

@ast

Effect of renal impairment on the pharmacokinetics of exenatide

@en

type

label

Effect of renal impairment on the pharmacokinetics of exenatide

@ast

Effect of renal impairment on the pharmacokinetics of exenatide

@en

prefLabel

Effect of renal impairment on the pharmacokinetics of exenatide

@ast

Effect of renal impairment on the pharmacokinetics of exenatide

@en

P1433

Q36024667-138E7432-AF7A-43E0-A83C-D2927152EA71

P1476

Q36024667-A3E24EDE-9EC2-4265-AF0D-534BDCF783B1

P2093

Q36024667-075205BC-D1FE-45F7-8E81-06C775430055

Q36024667-51F30661-4961-44BE-AC7F-BD1A1433E384

Q36024667-67B126AE-5A46-4402-8A5A-BAF02490FC58

Q36024667-82BD709E-3BDA-4EAE-B003-892CEE2CD470

Q36024667-8C6C7DD2-0D71-4BDB-9428-56C4E8A59B76

Q36024667-9694244E-2A8F-4118-A95F-0E98FBDE6CDD

Q36024667-99E562C8-3AFB-4B44-8337-3826863E41D5

P2860

Q36024667-15CC560B-4E53-4390-8B69-AF6F15FA0EF7

Q36024667-17546077-8E9B-4B44-AAF9-87413C6F239D

Q36024667-179B0155-09D2-4084-B9E4-EAA08A9255BB

Q36024667-23E7F221-02CC-45CF-8846-45E1600EEA1E

Q36024667-39649945-D65A-4FD3-B54A-56C959E9E3E1

Q36024667-4562D896-0F0F-4A86-9E15-43E718043EED

Q36024667-47B9571F-5722-4C32-9771-33CE7415EA55

Q36024667-4F579D18-F659-4749-AB0F-F67204F01E08

Q36024667-530DED0C-5B74-4C06-907B-1C79839DF66D

Q36024667-5A0328E6-4390-4D10-B2D6-481E87ED8F2F

P304

Q36024667-9F0FD7BB-600C-4EE3-A009-C12E24D7812A

P31

Q36024667-494206A7-C7B7-4360-8918-BF91590DDCE1

P356

Q36024667-683D1653-3A3B-4C84-8895-77CC8AD525DC

P407

Q36024667-D0C45811-4027-4783-AF87-E9737FBA122A

P433

Q36024667-3627AC36-420E-44C4-89DD-123B02B3292F

P478

Q36024667-90211D29-32BC-4473-B170-8B1FA2C38BFE

P577

Q36024667-A66D9D63-0A59-4330-85E4-EF7A63FA1D63

P5875

Q36024667-E926EE0C-EB65-401C-BE79-9505FCE2C708

P698

Q36024667-1AB247C8-0643-45D8-A514-31A43B8FAFD4

P932

Q36024667-1E276209-48EA-4C04-8999-6B19D9EF1284

P356

J.1365-2125.2007.02890.X

P1433

British Journal of Clinical Pharmacology

P1476

Effect of renal impairment on the pharmacokinetics of exenatide

@en

P2093

Helle Linnebjerg

http://www.w3.org/2001/XMLSchema#string

Kenneth Mace

http://www.w3.org/2001/XMLSchema#string

Malcolm Mitchell

http://www.w3.org/2001/XMLSchema#string

Prajakti A Kothare

http://www.w3.org/2001/XMLSchema#string

Robert Lins

http://www.w3.org/2001/XMLSchema#string

Shobha Reddy

http://www.w3.org/2001/XMLSchema#string

Soomin Park

http://www.w3.org/2001/XMLSchema#string

P2860

Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor

Glucagon-like peptide-1: regulation of insulin secretion and therapeutic potential.

Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor

Better glycaemic control and risk reduction of diabetic complications in Type 2 diabetes: comparison with the DCCT.

Relationship between blood glucose control, pathogenesis and progression of diabetic nephropathy.

New insights into the regulation of glucagon secretion by glucagon-like peptide-1.

Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes.

A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4).

Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes.

P304

317-327

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2125.2007.02890.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

64

http://www.w3.org/2001/XMLSchema#string

P577

2007-04-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51389812

http://www.w3.org/2001/XMLSchema#string

P698

17425627

http://www.w3.org/2001/XMLSchema#string

P932

2000650

http://www.w3.org/2001/XMLSchema#string